Biomarker Solutions for Steatotic Liver Disease. Enabling better insights into MASH / MASLD biology
Steatotic liver disease (SLD), including MASH and MASLD, is one of the most common forms of chronic liver disease, with an estimated prevalence of about 30% across many countries.
The I148M genotype variant of the PNPLA3 gene is associated with MASH / MASLD disease severity and fibrosis progression even in the absence of classical metabolic dysfunction (including obesity). Conversely SNPs within or close to the hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) gene is associated with reduced risk and severity of MASH / MASLD disease and as such both genes are of significant research interest to the field.
Almac Diagnostic Services has developed and validated both PNPLA3 & HSD17B13 Clinical Trial Assays for clinical trial use and also developed a PNPLA3 Genotyping kit for research use to enable researchers with better insights into MASH / MASLD biology.
This webinar explores some of the realities of a precision medicine approach to steatotic liver disease from a diagnostic providers perspective.
What you will learn:
- The importance of a precision medicine approach in Steatotic Liver Disease
- Developing liver genotyping assays that are highly accurate, sensitive & specific
- Almac PNPLA3 and HSD17B13 CTAs and Almac PNPLA3 Genotyping Kit Overview
- Assay utility and performance
- Future ideas
Who should listen?
This webinar will appeal to Pharma and Biotech companies working on chronic disease indication focus, in particular Steatotic Liver Disease including MASH / MASLD. This webinar will benefit decision makers with responsibilities including, but not limited to:
- Biomarker Programme / Project Management
- Clinical Development
- CDx Development
In addition, the webinar will also be interesting to Liver Disease Researchers doing basic liver research and who may be interested in a precision medicine approach, such as:
- Endocrinologists
- Hepatologists
- Gastroenterologists
Presenters:
Dr. Steven Walker, Director of Product Management, Almac Diagnostic Services
Dr. Steven Walker (PhD) heads up the product management activities at Almac Diagnostic Services. Specifically, this includes the development of novel biomarker assays towards commercialisation to aid Pharma & Biotech companies in their drug development programmes.
Steven studied at the University of Dundee, leading to a PhD before postgraduate work at the Beatson Cancer Research UK Institute in Glasgow. He joined Almac Diagnostic Services in 2005, initially with the research team before taking the role in Product Development. As part of his time with the research team, he was involved in the discovery and development of several of the internally discovered biomarker assays at Almac and led the development of novel products such as the Almac claraT Total mRNA report.
Dr. Cheryl McFarlane, Associate Director, Assay Development & Validation, Almac Diagnostic Services
Dr. Cheryl McFarlane (PhD) has worked for over 15 years in the field of translational molecular oncology and holds the post of Associate Director of Assay Development & Validation at Almac Diagnostic Services where she has responsibility for assay development and validation activities supporting biomarker discovery, development and delivery for a range of Global Biopharma clients.
Prior to joining Almac in 2015, Dr McFarlane obtained a PhD from Queen’s University Belfast. She subsequently completed postdoctoral fellowships where she specialised in the identification and validation of novel therapeutic targets in the Ubiquitin Proteasome system.
View Resource
